These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32321326)

  • 21. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incentives and disincentives to drug innovation: evidence from recent literature.
    Lee Mendoza R
    J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
    [No Abstract]   [Full Text] [Related]  

  • 23. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 24. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need.
    Dionne PA; Ali F; Grobler M
    J Health Econ Outcomes Res; 2015; 3(1):13-23. PubMed ID: 34430665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries?
    Cherla A; Howard N; Mossialos E
    Health Econ Policy Law; 2021 Apr; 16(2):113-123. PubMed ID: 32122423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the price right? Paying for value today to get more value tomorrow.
    Ramagopalan SV; Diaz J; Mitchell G; Garrison LP; Kolchinsky P
    BMC Med; 2024 Jan; 22(1):45. PubMed ID: 38287326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
    Lauenroth VD; Stargardt T
    Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 32. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
    Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
    J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Operationalizing value-based pricing of medicines : a taxonomy of approaches.
    Sussex J; Towse A; Devlin N
    Pharmacoeconomics; 2013 Jan; 31(1):1-10. PubMed ID: 23329588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The AMNOG and its consequences].
    Dingermann T
    Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The crisis in access to essential medicines in India: key issues which call for action.
    Bhargava A; Kalantri SP
    Indian J Med Ethics; 2013; 10(2):86-95. PubMed ID: 23697486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China.
    Sun X; Wei J; Yao Y; Chen Q; You D; Xu X; Dai J; Yao Y; Sheng J; Li X
    BMJ Open; 2018 Oct; 8(10):e023646. PubMed ID: 30341137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel perspective on pharmaceutical R&D costs: opportunities for reductions.
    van der Schans S; De Loos F; Boersma C; Postma MJ; Büller H
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):167-175. PubMed ID: 34595997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.